Purchase
Description
Eculizumab biosimilar is a recombinant humanized monoclonal IgG2/4κ antibody produced by Chinese hamster ovary cell culture and purified by standard bioprocess technology. Eculizumab biosimilar contains human constant regions from human IgG2 sequences and human IgG4 sequences and murine complementarity-determining regions grafted onto the human framework light- and heavy-chain variable regions. Eculiz umab biosimilaris composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148 kDa.
Eculizumab biosimilar is supplied at a concentration of 10 mg/mL as a sterile, preservative-free, clear, colorless solution of pH 7.0, which contains 0.46 mg/mL sodium phosphate monobasic, 1.78 mg/mL sodium phosphate dibasic, 8.77 mg/mL sodium chloride, 0.22 mg/mL polysorbate 80 (vegetable origin).
Statement: this product is used for R&D only, not for clinical usage.
Properties
|
Name
|
Eculizumab biosimilar
|
|
CAS
NO.
|
219685-50-4
|
|
Type
|
Whole
antibody
|
|
Source
|
Humanized (from mouse)
|
|
Target
|
Complement
protein C5
|
|
Clone
|
Monoclone
|
|
Molecular
Weight
|
148 kDa
|
|
Antibody
Form
|
Purified immunoglobulin
|
|
Physical
Form
|
Solution
|
|
Grade
Standard
|
Medicine Grade
|
|
Place
of Origin
|
China (Mainland)
|
|
Storage
|
-70±15℃ for long-term
storage, 2-8℃ for short-term storage, away from light.
|
Supply Ability
20 kilogram per year, Minimum order quantity is 1 gram.
Price
Inquiry
Material Safety Data Sheet
If you need more information, please contact us.
Certificate Of Analysis
/en/UploadFile/file/201805/2018050815400243243.rar
Detail information about the product please refer the website below：
https://en.wikipedia.org/wiki/Eculizumab
|
